Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study

BACKGROUND: Maintaining angiogenesis inhibition and switching the chemotherapy backbone represent the current second-line therapy in patients with RAS-mutant metastatic colorectal cancer (mCRC). Regorafenib, an oral multikinase inhibitor, prolonged overall survival (OS) in the chemorefractory settin...

Descripción completa

Detalles Bibliográficos
Autores principales: Cardone, C., De Stefano, A., Rosati, G., Cassata, A., Silvestro, L., Borrelli, M., Di Gennaro, E., Romano, C., Nappi, A., Zanaletti, N., Foschini, F., Casaretti, R., Tatangelo, F., Lastoria, S., Raddi, M., Bilancia, D., Granata, V., Setola, S., Petrillo, A., Vitagliano, C., Gargiulo, P., Arenare, L., Febbraro, A., Martinelli, E., Ciardiello, F., Delrio, P., Budillon, A., Piccirillo, M.C., Avallone, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024144/
https://www.ncbi.nlm.nih.gov/pubmed/36603521
http://dx.doi.org/10.1016/j.esmoop.2022.100748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024144/
https://www.ncbi.nlm.nih.gov/pubmed/36603521
http://dx.doi.org/10.1016/j.esmoop.2022.100748

Ejemplares similares